Why the study?
Postoperative ileus is frequently driven by sympathetic excitation, and dexmedetomidine lessens pain and inhibits sympathetic activity, prompting investigation into whether it promotes bowel movements after laparoscopic nephrectomy.
Does intravenous dexmedetomidine improve postoperative bowel movement recovery in patients undergoing laparoscopic nephrectomy?
Does intravenous dexmedetomidine improve postoperative bowel movement recovery in patients undergoing laparoscopic nephrectomy?
Postoperative infusion of dexmedetomidine facilitates bowel movement recovery and reduces pain in patients undergoing laparoscopic nephrectomy.
Answers are grounded in this paper and cite their sources.
Supports dexmedetomidine infusion to hasten bowel recovery after laparoscopic nephrectomy; extends RCT evidence for its perioperative use beyond analgesia.
Background Postoperative ileus is a frequent complication after surgery, especially abdominal surgery. Of the factors, sympathetic excitation is the primary factor for postoperative ileus. Sympathetic activation is always increased by the stress of surgery and postoperative pain. It was reported that dexmedetomidine (DEX) lessens pain and inhibits the sympathetic nerve by acting on the locus coeruleus. Therefore we designed our study to observe whether DEX promotes bowel movements in patients after laparoscopic nephrectomy. Methods One hundred and twenty patients undergoing laparoscopic nephrectomy were assigned into three groups, group C (normal saline infusion), group D1 (DEX 0.02 µg/kg/h), and group D2 (DEX 0.04 µg/kg/h). The primary outcome was to record the times of first flatus, defecation and eating after surgery. The secondary outcome was postoperative pain accessd by the numerical rating scale (NRS), concerning adverse effects, as well as the duration of the postoperative hospital stay. Results The times of first flatus, defecation and eating in groups D1 and D2 were shorter than those in group C (P<0.01). The NRS scores at 8 h and 24 h after surgery were obviously lower in groups D1 and D2 than in group C (P<0.05). There were no concerning adverse effects (P>0.05). Conclusion DEX in 0.04 µg/kg/h postoperative infusion facilitates bowel movements in patients undergoing laparoscopic nephrectomy. Trial registration This trial was registered in a Chinese Clinical Trial Registry (ChiCTR) center on December 23, 2015. The registered number was ChiCTR-IPR-15007628.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: